Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.33

-7.5%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$257.24M
EPS-1.4000
P/E Ratio-2.38
Earnings Date08/12/2026

catx

Total Current Assets

Last Annual Value

148.39M

3-Year CAGR

41%

5-Year CAGR

65%

10-Year CAGR

27%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of Total Current Assets

CATX · AMEX
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
148.39M
106.6%18.5%30.6% 
32.24M
15.6%-1.7%N/A
45.08M
6.1%7.3%11.0%
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
118.37M
-14.6%-15.2%22.3%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
247.47M
3.2%-16.7%N/A
61.55M
-13.1%-11.8%10.4%
HSDT logo
Solana Company
NASDAQ:HSDT
31.16M
62.2%19.9%N/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.33, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.33